Interleukin-7-enhanced cytotoxic T lymphocyte activity after viral infection in marrow transplanted mice

Bone Marrow Transplantation

Volumn 19, Issue 6, 1997, Pages 539-543

  Abdul Hai, A ^a   Ben Yehuda, A ^a   Weiss, L ^a   Friedman, G ^a   Zakay Rones, Z ^b   Slavin, S ^a   Or, R ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Bone marrow transplantation; Interleukin 7; T lymphocytes

Indexed keywords

RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFLUENZA VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; IRRADIATION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS INFECTION; VIRUS TITRATION;

EID: 0030894382     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700706     Document Type: Article

References (33)

1. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
2. Canellos GP, Nadler L, Takvorian T. Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Semin Hematol 1988; 25 (Suppl. 2): 58-65.
3. Bishop MR, Anderson JR, Jackson JD et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610-616.
4. Petersen FB, Buckner CD, Clift RA et al. Infectious complications in patients undergoing marrow transplantation: a prospective randomized study of the additional effect of decontamination and laminar air flow isolation among patients receiving prophylactic systemic antibiotics. Scan J Infect Dis 1987; 19: 559-567.
5. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
6. Wingard JR, Chen DY, Burns WH et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71: 1432-1437.
7. Abdul-Hai A, Lorberboum-Gliski H, Mechushtan A et al. Involvement of interleukin-2 in immunologic reconstitution following bone marrow transplantation in mice. J lnterf Cytokine Res 1995; 15: 95-101.
8. Namen AE, Lupton S, Hjerrild K et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988; 333: 571-573.
9. Goodwin RG, Lupton S, Schmierer A et al. Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci USA 1989; 86: 302-306.
10. Sakata T, Iwagami S, Tsuruta Y et al. Constitutive expression of interleukin-7 mRNA and production of IL-7 by a cloned murine thymic stromal cell line. J Leukocyte Biol 1990; 48: 205-212.
11. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin-7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 1990; 172: 577-587.
12. Muegge K, Vila MP, Durum SK. Interleukin-7: a cofactor for V(D)J rearrangement of the T cell receptor β gene. Science 1993; 261: 93-95.
13. Abdul-Hai A, Or R, Slavin S et al. Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice. Exp Hematol 1996; 24: 1416-1422.
14. Bolotin E, Smogorzewska M, Smith S et al. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 1996; 88: 1887-1894.
15. Ben-Yehuda R, Ehleiter D, Hu AR, Weksler ME. Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune response and increased susceptibility of old mice to influenza infection. J Infect Dis 1993; 168: 352-357.
16. Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza. Vaccine 1995; 13: 1-4.
17. Reed LJ, Muench M. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497.
18. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69: 369-380.
19. Lynch DH, Miller RE. Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol 1990; 145: 1983-1990.
20. Touw I, Pouwels K, van Agthoven T et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990; 75: 2097-2101.
21. Alderson MR, Tough TW, Ziegler SF, Grabstein KH. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991; 173: 923-930.
22. von Freeden-Jeffry U, Vieira P, Lucian LA et al. Lymphopenia in interleukin (IL)-7 gene-deleted mice indentifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181: 1519-1526.
23. Massumoto C, Benyunes MC, Sale G et al. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 1996; 17: 351-356.
24. Messina C, Zambello R, Rossetti F et al. lnterleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients. Bone Marrow Transplant 1996; 17: 729-735.
25. Valteau-Couanet D, Rubie H, Meresse Y et al. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 1995; 16: 515-520.
26. Robinson N, Sanders JE, Benyunes MC et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249-1254.
27. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graftversus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 1990; 87: 5633-5637.
28. + cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560-2569.
29. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest 1992; 10: 19-26.
30. Pavletic Z, Benyunes MC, Thompson JA et al. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy. Exp Hematol 1993; 21: 1371-1378.
31. Jicha D. Mule J, Rosenberg S. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcoma with efficacy in cellular adoptive immunotherapy. J Exp Med 1991; 174: 1511-1515.
32. Lynch D, Namen A, Miller R. In vivo evaluation of the effects of IL-2, IL-4 and IL-7 on enhancing the immunotherapeutic efficacy of anti-tumor CTL. Eur J lmmunol 1991; 21: 2977-2980.
33. Touw I, Pouwels K, van Agthoven T et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990; 75: 2097-2101.